- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Hayward Today
By the People, for the People
Pulse Biosciences Begins Clinical Trial for Cardiac Catheter
Company enrolls first patients in pivotal study of nPulse device for atrial fibrillation treatment.
Apr. 7, 2026 at 12:36pm
Got story updates? Submit your updates here. ›
A cutting-edge cardiac catheter device designed to precisely target and ablate irregular heart tissue, offering new hope for patients struggling with atrial fibrillation.Hayward TodayPulse Biosciences, a medical technology company, has enrolled the first patients in a pivotal clinical study evaluating its nPulse Cardiac Catheter for the treatment of atrial fibrillation. The NANOPULSE-AF IDE study will assess the safety and efficacy of the nPulse device, which uses nanosecond pulsed electric fields to ablate cardiac tissue.
Why it matters
Atrial fibrillation is a common heart rhythm disorder that can lead to serious complications if left untreated. The nPulse Cardiac Catheter represents a potential new treatment option that could improve outcomes for patients with this condition. The successful completion of this pivotal study could pave the way for regulatory approval and wider adoption of the device.
The details
The NANOPULSE-AF IDE study will enroll up to 400 patients at multiple clinical sites. The nPulse Cardiac Catheter is designed to deliver nanosecond pulsed electric fields to selectively ablate cardiac tissue and restore normal heart rhythm in patients with atrial fibrillation. This non-thermal ablation approach aims to minimize collateral damage to surrounding tissues compared to traditional radiofrequency or cryoablation techniques.
- Pulse Biosciences enrolled the first patients in the NANOPULSE-AF IDE study on April 7, 2026.
The players
Pulse Biosciences
A medical technology company developing novel therapies for the treatment of various diseases and conditions.
What’s next
The NANOPULSE-AF IDE study is expected to continue enrolling patients over the next 12-18 months, with topline results anticipated in 2028.
The takeaway
The initiation of this pivotal clinical trial for the nPulse Cardiac Catheter represents an important milestone in the development of a potentially groundbreaking new treatment for atrial fibrillation, a condition that affects millions of people worldwide.
